|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.1910 - 0.2000|
|52 Week Range||0.0500 - 0.3100|
|Beta (3Y Monthly)||3.39|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 11, 2019 - Apr 15, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||0.55|
SOUTH SAN FRANCISCO, Calif., May 15, 2019 -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan.
Mateon Therapeutics, Inc. (MATN) and Oncotelic Inc. announced today that they have completed their previously announced merger. The combined company has a focused pipeline of TGF-β RNA Therapeutics for late stage cancers, including gliomas, pancreatic cancer and melanoma.
Mateon Therapeutics, Inc. (MATN) and Oncotelic Inc., a privately-held, late clinical-stage cancer immunotherapy company, announced today that they have entered into a definitive agreement with respect to a merger, creating a publicly traded immuno-oncology company with a robust pipeline of first in class TGF-β immunotherapies for late stage cancers such as gliomas, pancreatic cancer and melanoma. “We believe that the merger of Oncotelic and Mateon will create a combined company that can generate shareholder value through a promising pipeline of next generation immunotherapies targeting several significant cancer markets where there is a paucity of therapeutic options and lack of an effective immunotherapy protocol,” said Vuong Trieu, Ph.D., Co-Founder, Chairman and Chief Executive Officer of Oncotelic.
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2018 -- Mateon Therapeutics, Inc. (OTCQB:MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan.
Mateon Therapeutics, Inc. (Mateon) is a clinical stage biopharmaceutical company that develops small molecule injectable drugs for the treatment of cancer patients, specifically targeting orphan indications. The Company is currently focused on advancing two programs, CA4P as an immuno-oncology agent for advanced metastatic melanoma and OXi4503 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and related myelodysplastic syndromes (MDS), with the ultimate goal of selling rights to a larger pharma player following additional clinical data.